Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2019 Jun;95:54-57. doi: 10.3899/jrheum.190121.

PMID:
31154406
2.
3.

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.

Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin CY, Birt J, Shuler CL, Hufford MM, Thaçi D.

Ann Rheum Dis. 2019 May 21. pii: annrheumdis-2018-215003. doi: 10.1136/annrheumdis-2018-215003. [Epub ahead of print]

PMID:
31113794
4.

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ.

Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.

5.

Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis.

Smith CJF, Bandoli G, Kavanaugh A, Chambers CD.

Arthritis Care Res (Hoboken). 2019 May 10. doi: 10.1002/acr.23924. [Epub ahead of print]

PMID:
31074583
6.

Pro- and anti-inflammatory eicosanoids in psoriatic arthritis.

Coras R, Kavanaugh A, Boyd T, Huynh Q, Pedersen B, Armando AM, Dahlberg-Wright S, Marsal S, Jain M, Paravar T, Quehenberger O, Guma M.

Metabolomics. 2019 Apr 19;15(4):65. doi: 10.1007/s11306-019-1527-0.

PMID:
31004236
7.

Efficacy and Safety of Intravenous Golimumab through 1 Year in Patients with Active Psoriatic Arthritis.

Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.

Arthritis Care Res (Hoboken). 2019 Apr 12. doi: 10.1002/acr.23905. [Epub ahead of print]

PMID:
30980514
8.

Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate-treated rheumatoid arthritis patients in OPTIMA.

Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H.

Clin Exp Rheumatol. 2019 Apr 9. [Epub ahead of print]

PMID:
30963994
9.

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin C, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study.

J Rheumatol. 2019 Apr 1. pii: jrheum.180792. doi: 10.3899/jrheum.180792. [Epub ahead of print]

PMID:
30936281
10.

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU.

BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018.

11.

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.

J Rheumatol. 2019 Mar 1. pii: jrheum.180971. doi: 10.3899/jrheum.180971. [Epub ahead of print]

12.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13. Review.

PMID:
30772098
13.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13. Review.

PMID:
30772097
14.

Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.

Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, Hsia EC.

J Rheumatol. 2019 Jun;46(6):595-602. doi: 10.3899/jrheum.180681. Epub 2019 Feb 15.

15.

Techniques for improving the initial strength of the tibial tray-cement interface bond.

Billi F, Kavanaugh A, Schmalzried H, Schmalzried TP.

Bone Joint J. 2019 Jan;101-B(1_Supple_A):53-58. doi: 10.1302/0301-620X.101B1.BJJ-2018-0500.R1.

PMID:
30648489
16.

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ.

J Rheumatol. 2019 May;46(5):475-482. doi: 10.3899/jrheum.171034. Epub 2019 Jan 15.

PMID:
30647182
17.

Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis.

Coras R, Kavanaugh A, Boyd T, Huynh D, Lagerborg KA, Xu YJ, Rosenthal SB, Jain M, Guma M.

Clin Exp Rheumatol. 2019 May-Jun;37(3):481-484. Epub 2019 Jan 4.

PMID:
30620278
18.

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.

Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, Benichou O, Lin CY, Nash P.

Clin Exp Rheumatol. 2018 Nov 19. [Epub ahead of print]

PMID:
30557128
19.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

20.

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, Schwebig A.

RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018.

21.

Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial.

Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M.

RMD Open. 2018 Oct 11;4(2):e000729. doi: 10.1136/rmdopen-2018-000729. eCollection 2018.

22.

Golimumab in the treatment of psoriatic arthritis.

Love TJ, Kavanaugh A.

Expert Rev Clin Immunol. 2018 Nov;14(11):893-898. doi: 10.1080/1744666X.2018.1524755. Epub 2018 Sep 27.

PMID:
30221556
23.

The role of golimumab in inflammatory arthritis. A review of the evidence.

Tahir Z, Kavanaugh A.

Ther Adv Musculoskelet Dis. 2018 Sep 6;10(9):181-194. doi: 10.1177/1759720X18793317. eCollection 2018 Sep. Review.

24.

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Mpofu S, Pricop L.

RMD Open. 2018 Aug 13;4(2):e000723. doi: 10.1136/rmdopen-2018-000723. eCollection 2018. Erratum in: RMD Open. 2018 Sep 7;4(2):e000723corr1.

25.

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.

Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A.

Ann Rheum Dis. 2018 Nov;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502. Epub 2018 Aug 3.

26.

Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis.

Narasimhan R, Coras R, Rosenthal SB, Sweeney SR, Lodi A, Tiziani S, Boyle D, Kavanaugh A, Guma M.

Arthritis Res Ther. 2018 Aug 3;20(1):164. doi: 10.1186/s13075-018-1655-3.

27.

Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.

Haugeberg G, Michelsen B, Tengesdal S, Hansen IJW, Diamantopoulos A, Kavanaugh A.

Arthritis Res Ther. 2018 Aug 2;20(1):160. doi: 10.1186/s13075-018-1659-z.

28.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ.

RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

29.

Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population.

Gulati AM, Michelsen B, Diamantopoulos A, Grandaunet B, Salvesen Ø, Kavanaugh A, Hoff M, Haugeberg G.

RMD Open. 2018 Jun 17;4(1):e000631. doi: 10.1136/rmdopen-2017-000631. eCollection 2018.

30.

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD.

J Rheumatol. 2018 Oct;45(10):1389-1396. doi: 10.3899/jrheum.171094. Epub 2018 Jul 1.

31.

Injuries in Collegiate Women's Volleyball: A Four-Year Retrospective Analysis.

Sole CJ, Kavanaugh AA, Stone MH.

Sports (Basel). 2017 May 10;5(2). pii: E26. doi: 10.3390/sports5020026.

32.

Impact of High-Intensity Interval Training on Disease Activity and Disease in Patients With Psoriatic Arthritis: A Randomized Controlled Trial.

Thomsen RS, Nilsen TIL, Haugeberg G, Bye A, Kavanaugh A, Hoff M.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):530-537. doi: 10.1002/acr.23614.

PMID:
29882634
33.

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.

Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J.

Clin Rheumatol. 2018 Aug;37(8):2275-2280. doi: 10.1007/s10067-018-4140-0. Epub 2018 Jun 4.

34.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
35.

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.

Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS.

Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7. Epub 2018 May 14.

36.

Macrophage Biocompatibility of CoCr Wear Particles Produced under Polarization in Hyaluronic Acid Aqueous Solution.

Perez-Maceda BT, López-Fernández ME, Díaz I, Kavanaugh A, Billi F, Escudero ML, García-Alonso MC, Lozano RM.

Materials (Basel). 2018 May 8;11(5). pii: E756. doi: 10.3390/ma11050756.

37.

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD.

RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018.

38.

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.

van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF.

RMD Open. 2018 Apr 9;4(1):e000659. doi: 10.1136/rmdopen-2018-000659. eCollection 2018.

39.

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.

Genovese M, Westhovens R, Meuleners L, Van der Aa A, Harrison P, Tasset C, Kavanaugh A.

Arthritis Res Ther. 2018 Mar 23;20(1):57. doi: 10.1186/s13075-018-1541-z.

40.

Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT).

Gulati AM, Salvesen Ø, Thomsen RS, Kavanaugh A, Semb AG, Rollefstad S, Haugeberg G, Hoff M.

RMD Open. 2018 Mar 14;4(1):e000630. doi: 10.1136/rmdopen-2017-000630. eCollection 2018.

41.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
42.

Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions.

Smith CJF, Jones KL, Johnson DL, Bandoli G, Robinson LK, Kavanaugh A, Chambers CD.

Am J Med Genet A. 2018 Mar;176(3):570-577. doi: 10.1002/ajmg.a.38594. Epub 2018 Jan 17.

43.

Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons.

Chen B, Zhao Y, Cheng X, Ma Y, Chang EY, Kavanaugh A, Liu S, Du J.

Magn Reson Imaging. 2018 Jun;49:4-9. doi: 10.1016/j.mri.2017.12.034. Epub 2018 Jan 5.

PMID:
29309823
44.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

45.

Characteristics of a National Level Female Weightlifter Peaking for Competition: A Case Study.

Bazyler CD, Mizuguchi S, Zourdos MC, Sato K, Kavanaugh AA, DeWeese BH, Breuel KF, Stone MH.

J Strength Cond Res. 2018 Nov;32(11):3029-3038. doi: 10.1519/JSC.0000000000002379.

PMID:
29200094
46.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

47.

Rheumatoid arthritis: Do TNF inhibitors influence lymphoma development?

Kavanaugh A.

Nat Rev Rheumatol. 2017 Nov 21;13(12):697-698. doi: 10.1038/nrrheum.2017.186. No abstract available.

PMID:
29158571
48.

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.

Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guérette B, Kupper H, Smolen JS.

Ann Rheum Dis. 2018 Feb;77(2):289-292. doi: 10.1136/annrheumdis-2017-211871. Epub 2017 Nov 16.

49.

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1198-1205. doi: 10.1002/acr.23460. Epub 2018 Jun 28.

50.

Returners Exhibit Greater Jumping Performance Improvements During a Peaking Phase Compared With New Players on a Volleyball Team.

Bazyler CD, Mizuguchi S, Kavanaugh AA, McMahon JJ, Comfort P, Stone MH.

Int J Sports Physiol Perform. 2018 Jul 1;13(6):709-716. doi: 10.1123/ijspp.2017-0474. Epub 2018 Jun 21.

PMID:
29035592

Supplemental Content

Loading ...
Support Center